Table 2 Adverse Events graded based on CTCAE 4.0
From: Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Adverse event | Grade 1* (n, %) | Grade 2 (n, %) | Grade 3 (n, %) | Total |
|---|---|---|---|---|
Hand-foot syndrome | 4(10.5) | 12(31.6) | 4(10.5) | 20(52.6) |
Proteinuria | 5(13.2) | 13(34.2) | 2(5.3) | 20(52.6) |
Hypertension | 1(2.6) | 7(18.4) | 8(21.1) | 16(42.1) |
Pain | 7(18.4) | 4(10.5) | 1(2.6) | 12(31.6) |
Neutropenia | 4(10.5) | 4(10.5) | 1(2.6) | 9(23.7) |
Bilirubin increased | 2(5.3) | 5(13.2) | - | 7(18.4) |
Transaminase increased | 5(13.2) | 1(2.6) | 1(2.6) | 7(18.4) |
Fatigue | 3(7.9) | 2(5.3) | 1(2.6) | 6(15.8) |
Mucositis | - | 5(13.2) | 1(2.6) | 6(15.8) |
Thrombocytopenia | 4(10.5) | 1(2.6) | - | 5(13.2) |
Hematuria | 4(10.5) | - | - | 4(10.5) |
Anorexia | - | 2(5.3) | 1(2.6) | 3(7.9) |
Dizziness | 2(5.3) | 1(2.6) | - | 3(7.9) |
Fever | 2(5.3) | - | - | 2(5.3) |
Diarrhea | 1(2.6) | 1(2.6) | - | 2(5.3) |
Skin ulceration | - | 1(2.6) | 1(2.6) | 2(5.3) |
Vomiting | 1(2.6) | - | - | 1(2.6) |
Ventricular arrhythmia | 1(2.6) | - | - | 1(2.6) |
Dyspnea | - | 1(2.6) | - | 1(2.6) |